1. Home
  2. GL vs EXAS Comparison

GL vs EXAS Comparison

Compare GL & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globe Life Inc.

GL

Globe Life Inc.

HOLD

Current Price

$131.30

Market Cap

11.0B

Sector

Finance

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.08

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GL
EXAS
Founded
1900
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
11.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GL
EXAS
Price
$131.30
$101.08
Analyst Decision
Buy
Buy
Analyst Count
10
20
Target Price
$151.50
$76.38
AVG Volume (30 Days)
476.4K
10.3M
Earning Date
10-22-2025
11-03-2025
Dividend Yield
0.82%
N/A
EPS Growth
16.72
N/A
EPS
13.77
N/A
Revenue
$5,940,974,000.00
$3,082,033,000.00
Revenue This Year
$7.51
$19.40
Revenue Next Year
$5.15
$13.51
P/E Ratio
$9.54
N/A
Revenue Growth
3.73
14.47
52 Week Low
$100.62
$38.81
52 Week High
$147.83
$101.87

Technical Indicators

Market Signals
Indicator
GL
EXAS
Relative Strength Index (RSI) 42.97 89.74
Support Level $129.21 $100.98
Resistance Level $132.02 $101.43
Average True Range (ATR) 2.33 2.25
MACD -0.05 0.53
Stochastic Oscillator 26.80 97.74

Price Performance

Historical Comparison
GL
EXAS

About GL Globe Life Inc.

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: